Daiichi Sankyo Company, Limited

OTCPK:DSKY.F Stock Report

Market Cap: US$36.7b

Daiichi Sankyo Company Valuation

Is DSKY.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of DSKY.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: DSKY.F ($20.09) is trading below our estimate of future cash flow value ($40.68)

Significantly Below Future Cash Flow Value: DSKY.F is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DSKY.F?

Key metric: As DSKY.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for DSKY.F. This is calculated by dividing DSKY.F's market cap by their current earnings.
What is DSKY.F's PE Ratio?
PE Ratio20.8x
EarningsJP¥279.90b
Market CapJP¥5.81t

Price to Earnings Ratio vs Peers

How does DSKY.F's PE Ratio compare to its peers?

The above table shows the PE ratio for DSKY.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28.1x
TEVA Teva Pharmaceutical Industries
50.9x11.54%US$36.0b
ZTS Zoetis
20.7x6.22%US$55.1b
RPRX Royalty Pharma
22.4x5.27%US$22.9b
BMY Bristol-Myers Squibb
18.5x1.47%US$110.9b
DSKY.F Daiichi Sankyo Company
20.8x15.78%US$5.8t

Price-To-Earnings vs Peers: DSKY.F is good value based on its Price-To-Earnings Ratio (20.8x) compared to the peer average (28.1x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does DSKY.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

8 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NDOI Endo
0.3xn/aUS$1.76b
CRMD CorMedix
3.6x2.02%US$586.19m
ORMP Oramed Pharmaceuticals
3xn/aUS$136.92m
BTMD biote
2.6x-52.79%US$104.57m
DSKY.F 20.8xIndustry Avg. 19.6xNo. of Companies8PE01632486480+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: DSKY.F is expensive based on its Price-To-Earnings Ratio (20.8x) compared to the US Pharmaceuticals industry average (19.6x).

Price to Earnings Ratio vs Fair Ratio

What is DSKY.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DSKY.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio20.8x
Fair PE Ratio30.4x

Price-To-Earnings vs Fair Ratio: DSKY.F is good value based on its Price-To-Earnings Ratio (20.8x) compared to the estimated Fair Price-To-Earnings Ratio (30.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DSKY.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$20.09
US$34.37
+71.07%
10.45%US$39.78US$28.41n/a16
Jan ’27US$21.50
US$35.14
+63.44%
10.23%US$40.48US$28.92n/a16
Dec ’26US$23.59
US$35.68
+51.25%
11.30%US$43.75US$28.95n/a17
Nov ’26US$23.13
US$35.49
+53.49%
12.51%US$44.13US$29.20n/a17
Oct ’26US$22.98
US$37.47
+63.04%
12.80%US$46.23US$30.59n/a17
Sep ’26US$23.59
US$37.44
+58.72%
12.80%US$46.20US$30.57n/a17
Aug ’26US$24.34
US$37.37
+53.52%
13.25%US$45.09US$29.84n/a17
Jul ’26US$22.90
US$40.46
+76.68%
10.79%US$45.37US$31.17n/a17
Jun ’26US$26.94
US$40.97
+52.07%
11.17%US$47.96US$31.28n/a18
May ’26US$26.63
US$41.53
+56.00%
10.09%US$48.28US$32.19n/a18
Apr ’26US$24.15
US$40.40
+67.28%
11.81%US$50.80US$30.74n/a18
Mar ’26US$22.90
US$41.01
+79.08%
9.00%US$50.49US$33.22n/a18
Feb ’26US$27.18
US$39.98
+47.09%
7.88%US$49.01US$35.46n/a18
Jan ’26US$26.60
US$40.11
+50.79%
8.88%US$48.34US$34.99US$21.5018
Dec ’25US$32.74
US$42.17
+28.81%
8.85%US$50.78US$36.75US$23.5918
Nov ’25US$32.13
US$42.76
+33.11%
7.14%US$50.02US$36.20US$23.1318
Oct ’25US$34.44
US$45.92
+33.33%
7.39%US$53.35US$38.61US$22.9817
Sep ’25US$39.59
US$45.01
+13.70%
10.04%US$58.05US$37.24US$23.5916
Aug ’25US$39.98
US$43.70
+9.31%
9.88%US$57.25US$36.72US$24.3416
Jul ’25US$32.87
US$39.09
+18.92%
8.05%US$43.04US$31.01US$22.9015
Jun ’25US$35.41
US$38.10
+7.58%
12.12%US$43.34US$26.77US$26.9415
May ’25US$34.35
US$35.93
+4.60%
9.42%US$39.90US$26.60US$26.6315
Apr ’25US$31.44
US$37.49
+19.24%
9.85%US$42.02US$28.02US$24.1515
Mar ’25US$32.50
US$37.49
+15.35%
9.85%US$42.02US$28.02US$22.9015
Feb ’25US$31.26
US$36.56
+16.94%
10.04%US$42.13US$28.54US$27.1815
Jan ’25US$26.61
US$37.43
+40.66%
10.42%US$43.54US$29.49US$26.6015
US$34.84
Fair Value
42.3% undervalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/22 13:59
End of Day Share Price 2026/01/22 00:00
Earnings2025/09/30
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Daiichi Sankyo Company, Limited is covered by 26 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Miki SogiBernstein
Koichi MameganoBofA Global Research